Biosimilar drugs' cost-savings still out of reach

The prospect of reducing health care costs through use of biosimilar drugs has has hit roadblocks in the form of setbacks for development programs and regulatory hurdles. The FDA is still crafting a pathway for approval. "There has been a little bit of volatility" in the push for biosimilars, said Merck vice president Richard Murray as the company formed a new partnership with Samsung.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief: